Home » Stocks » Spruce Biosciences

Spruce Biosciences, Inc. (SPRB)

Stock Price: $16.92 USD 0.11 (0.65%)
Updated Oct 21, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 392.01M
Revenue (ttm) n/a
Net Income (ttm) -17.35M
Shares Out 22.26M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $16.92
Previous Close $16.81
Change ($) 0.11
Change (%) 0.65%
Day's Open 16.91
Day's Range 16.09 - 17.00
Day's Volume 163,706
52-Week Range 15.12 - 18.49

More Stats

Market Cap 392.01M
Enterprise Value 359.65M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 22.26M
Float 19.08M
EPS (basic) n/a
EPS (diluted) -0.78
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.14
Revenue n/a
Operating Income n/a
Net Income -17.35M
Free Cash Flow n/a
Net Cash 32.35M
Net Cash / Share 1.40
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-13.11-9.97
Net Income-13.09-9.86
Shares Outstanding5.004.91
Earnings Per Share-2.62-2.01
Operating Cash Flow-12.62-8.57
Capital Expenditures--
Free Cash Flow-12.62-8.57
Cash & Equivalents3.924.11
Total Debt4.45-
Net Cash / Debt-0.524.11
Book Value-30.64-17.80
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Spruce Biosciences, Inc.
Country United States
Employees 15
CEO Richard A. King

Stock Information

Ticker Symbol SPRB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SPRB
IPO Date October 9, 2020


Spruce Biosciences, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.